# Viking Therapeutics, Inc.: overview

VKTX · Nasdaq · CIK 1607678 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vktx.md) · [Financials](/companies/vktx/financials.md) · [Filings](/companies/vktx/filings.md) · [Insiders](/companies/vktx/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-324219.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-324219).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | [0.0](/filings/0001193125-25-247059.md) | [0.0 d](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-193315.md) | [0.0](/filings/0001193125-26-324219.md) | [0.0](/filings/0001193125-25-247059.md) | [0.0 d](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-193315.md) | [0.0](/filings/0001193125-26-324219.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.22)](/filings/0001193125-25-247059.md) | not reported | [(0.41)](/filings/0001193125-26-193315.md) | [(0.58)](/filings/0001193125-26-324219.md) | [(0.81)](/filings/0001193125-25-247059.md) | not reported | [(1.37)](/filings/0001193125-26-193315.md) | [(1.10)](/filings/0001193125-26-324219.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $ | [0.0](/filings/0000950170-24-012322.md) | [0.0](/filings/0000950170-25-027824.md) | [0.0](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-046876.md) | [0.0](/filings/0001193125-26-046876.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.71)](/filings/0000950170-24-012322.md) | [(0.90)](/filings/0000950170-25-027824.md) | [(0.91)](/filings/0001193125-26-046876.md) | [(1.01)](/filings/0001193125-26-046876.md) | [(3.19)](/filings/0001193125-26-046876.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/vktx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $247.2m | 6,335,756 |  | Added +311,003 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $241.5m | 6,189,649 |  | Reduced −690,641 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $218.7m | 5,606,394 |  | Added +1,210,837 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $197.1m | 5,053,663 |  | Added +41,161 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $174.9m | 4,484,263 |  | Added +19,965 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $153.6m | 3,937,414 |  | Reduced −494,728 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $136.0m | 3,486,040 |  | Added +472,112 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $113.4m | 2,906,500 | Call | Reduced −251,500 |
| [AMERIPRISE FINANCIAL INC](/funds/820027.md) | 2026-06-30 | $84.1m | 2,156,083 |  | Added +477,338 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $81.9m | 2,097,981 |  | Added +15,914 |

## Recent filings

[All 626 filings](/companies/vktx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-09-28 | 17:27 ET | [8-K](/filings/0001193125-26-405580.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-405580 |
| 2026-09-22 | 07:06 ET | [8-K](/filings/0001193125-26-397219.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-397219 |
| 2026-07-29 | 17:15 ET | [10-Q](/filings/0001193125-26-324219.md) | Quarterly report, period 2026-06-30 | 0001193125-26-324219 |
| 2026-07-29 | 16:05 ET | [8-K](/filings/0001193125-26-323652.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-323652 |
| 2026-05-26 | 16:48 ET | [8-K](/filings/0001193125-26-239535.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-239535 |
| 2026-04-30 | 21:50 ET | [10-Q](/filings/0001193125-26-193315.md) | Quarterly report, period 2026-03-31 | 0001193125-26-193315 |
| 2026-04-29 | 16:05 ET | [8-K](/filings/0001193125-26-191487.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-191487 |
| 2026-04-01 | 16:14 ET | [DEF 14A](/filings/0001193125-26-137915.md) | Proxy statement, period 2026-05-19 | 0001193125-26-137915 |
| 2026-02-11 | 17:25 ET | [10-K](/filings/0001193125-26-046876.md) | Annual report, period 2025-12-31 | 0001193125-26-046876 |
| 2026-02-11 | 16:06 ET | [8-K](/filings/0001193125-26-046536.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-046536 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-046876.md), filed Feb 11, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d0a78237-b239-4674-8f76-a45f3edb2b08)

## About the filer

- CIK: 1607678
- Tickers: VKTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.